Monoclonal antibody therapeutics and apoptosis

Oncogene

Volumn 22, Issue 56 REV. ISS. 8, 2003, Pages 9097-9106

  Ludwig, Dale L ^a   Pereira, Daniel S ^a   Zhu, Zhenping ^a   Hicklin, Daniel J ^a   Bohlen, Peter ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Anti angiogenesis; Cancer; ErbB; Immunoglobulin; Receptor tyrosine kinase; TRAIL

Indexed keywords

ALEMTUZUMAB; ANGIOGENESIS INHIBITOR; ANTIBODY CONJUGATE; BEVACIZUMAB; BL 22; CETUXIMAB; DEATH RECEPTOR 4; DEATH RECEPTOR 5; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; IMC 1C11; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOGLOBULIN G4 ANTIBODY; MONOCLONAL ANTIBODY; PLATELET DERIVED GROWTH FACTOR RECEPTOR; RITUXIMAB; SOMATOMEDIN C RECEPTOR; TOSITUMOMAB I 131; TRAIL RECEPTOR 1 ANTIBODY; TRASTUZUMAB; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR; ZD 2767P;

ANGIOGENESIS; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BETA RADIATION; CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CELL SURVIVAL; CLINICAL TRIAL; COMPLEMENT DEPENDENT CYTOTOXICITY; CROSS LINKING; DRUG CONJUGATION; DRUG MECHANISM; HUMAN; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; REVIEW; TARGET CELL DESTRUCTION; TUMOR VASCULARIZATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIVISION; CELL SURVIVAL; HUMANS; IMMUNOTOXINS; MODELS, BIOLOGICAL; SIGNAL TRANSDUCTION;

EID: 1642553419     PISSN: 09509232     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.onc.1207104     Document Type: Review

References (143)

1. Alimandi M, Romano A, Curia MC, Muraro R, Fedi P, Aaronson SA, Di Fiore PP and Kraus MH. (1995). Oncogene, 10, 1813-1821.
2. Arteaga CL. (2002). Oncologist, 7S4, 31-39.
3. Ashkenazi A and Dixit VM. (1998). Science, 281, 1305-1308.
4. Baek JH, Jang JE, Kang CM, Chung HY, Kim ND and Kim KW. (2000). Oncogene, 19, 4621-4631.
5. Baetu TM and Hiscott J. (2002). Cytokine Growth Factor Rev., 13, 199-207.
6. Bagshawe KD and Begent RHJ. (1996). Adv. Drug Deliv. Rev., 22, 365-367.
7. Bandyopadhyay D, Mandal M, Adam L, Mendelsohn J and Kumar R. (1998). J. Biol. Chem., 273, 1568-1573.
8. Baselga J. (2002). Oncologist, 7S4, 2-8.
9. Baselga J, Norton L, Masui H, Pandiella A, Coplan K, Miller Jr WH and Mendelsohn J. (1993). J. Natl. Cancer Inst., 85, 1327-1333.
10. Benini S, Manara MC, Baldini N, Cerisano V, Massimo Serra, Mercuri M, Lollini PL, Nanni P, Picci P and Scotlandi K. (2001). Clin. Cancer Res., 7, 1790-1797.
11. Bianco C, Bianco R, Tortora G, Damiano V, Guerrieri P, Montemaggi P, Mendelsohn J, De Placido S, Bianco AR and Ciardiello F. (2000). Clin. Cancer Res., 6, 4343-4350.
12. Boulianne GL, Hozumi N and Shulman MJ. (1984). Nature, 312, 643-646.
13. Bruns CJ, Liu W, Davis DW, Shaheen RM, McConkey DJ, Wilson MR, Bucana CD, Hicklin DJ and Ellis LM. (2000). Cancer, 89, 488-499.
14. Bruns CJ, Shrader M, Harbison MT, Portera C, Solorzano CC, Jauch KW, Hicklin DJ, Radinsky R and Ellis LM. (2002). Int. J. Cancer, 102, 101-108.
15. Burgering BM and Coffer PJ. (1995). Nature, 376, 599-602.
16. Byrd JC, Kitada S, Flinn IW, Aron JL, Pearson M, Lucas D and Reed JC. (2002). Blood, 99, 1038-1043.
17. Cantley LC. (2002). Science, 296, 1655-1657.
18. Cardarelli PM, Quinn M, Buckman D, Fang Y, Colcher D, King DJ, Bebbington C and Yarranton G. (2002). Cancer Immunol. Immunother., 51, 15-24.
19. Carmeliet P and Jain RK. (2000). Nature, 407, 249-257.
20. Carter P. (2001). Nat. Rev: Cancer, 1, 118-129.
21. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME and Shepard HM. (1992). Proc. Natl. Acad. Sci. USA, 89, 4285-4289.
22. Ciardiello F, Bianco R, Damiano V, De Lorenzo S, Pepe S, De Placido S, Fan Z, Mendelsohn J, Bianco AR and Tortora G. (1999). Clin. Cancer Res., 5, 909-916.
23. Clynes RA, Towers TL, Presta LG and Ravetch JV. (2000). Nat. Med., 6, 443-446.
24. Danielsen AJ and Maihle NJ. (2002). Growth Factors, 20, 1-15.
25. Datta SR, Brunet A and Greenberg ME. (1999). Genes Dev., 13, 2905-2927.
26. Deardon C. (2002). Biodrugs, 16, 283-301.
27. de Bono JS and Rowinsky EK. (2002). Trends Mol. Med., 8S4, S19-S26.
28. de Haard HJ, van Neer N, Reurs A, Hufton SE, Roovers RC, Henderikx P, de Bruine AP, Arends JW and Hoogenboom HR. (1999). J. Biol. Chem., 274, 18218-18230.
29. De Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N and Williams LT. (1992). Science, 255, 989-991.
30. Dias S, Hattori K, Heissig B, Zhu Z, Wu Y, Witte L, Hicklin DJ, Tateno M, Bohlen P, Moore MA and Rafii S. (2001). Proc. Natl. Acad. Sci. USA, 98, 10857-10862.
31. Dias S, Hattori K, Zhu Z, Heissig B, Choy M, Lane W, Wu Y, Chadburn A, Hyjek E, Gill M, Hicklin DJ, Witte L, Moore MA and Rafii S. (2000). J. Clin. Invest., 106, 511-521.
32. Dougall WC, Qian X, Peterson NC, Miller MJ, Samanta A and Greene MI. (1994). Oncogene, 9, 2109-2123.
33. Ekedahl J, Joseph B, Grigoriev MY, Muller M, Magnusson C, Lewensohn R and Zhivotovsky B. (2002). Exp. Cell Res., 279, 277-290.
34. Ferrara N. (1995). Breast Cancer Res. Treat., 36, 127-137.
35. Findley HW and Zhou M. (1999). Leukemia, 13, 147-149.
36. Fischer-Colbrie J, Witt A, Heinzl H, Speiser P, Czerwenka K, Sevelda P and Zeillinger R. (1997). Anticancer Res., 17, 613-619.
37. Folkman J. (1991). J. Natl. Cancer Inst., 82, 4-6.
38. Folkman J. (1995). Nat. Med., 1, 27-31.
39. Gerber HP, Dixit V and Ferrara N. (1998a). J. Biol. Chem., 273, 13313-13316.
40. Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V and Ferrara N. (1998b). J. Biol. Chem., 273, 30336-30343.
41. Ghetie MA, Bright H and Vitetta ES. (2001). Blood, 97, 1392-1398.
42. Gille H, Kowaski J, Li B, Lecouter J, Moffat B, Zioncheck TF, Pelletier N and Ferrara N. (2001). J. Biol. Chem., 276, 3222-3230.
43. Glennie MJ and Johnson PW. (2001). Immunol. Today, 21, 403-410.
44. Gupta VK, Jaskowiak NT, Beckett MA, Mauceri HJ, Grunstein J, Johnson RS, Calvin DA, Nodzenski E, Pejovic M, Kufe DW, Posner MC and Weichselbaum RR. (2002). Cancer J., 8, 47-54.
45. Harmey JH and Bouchier-Hayes D. (2002). BioEssays, 24, 280-283.
46. Hengartner MO. (2000). Nature, 407, 770-776.
47. Hoogenboom HR and Chames P. (2000). Immunol. Today, 21, 371-378.
48. Hu L, Hofmann J, Zaloudek C, Ferrara N, Hamilton T and Jaffe RB. (2002). Am. J. Pathol., 161, 1917-1924.
49. Huang SM, Bock JM and Harari PM. (1999). Cancer Res., 59, 1935-1940.
50. Huang SM and Harari PM. (1999). Invest. New Drugs 17, 259-269.
51. Huang SM and Harari PM. (2000). Clin. Cancer Res., 6, 2166-2174.
52. Ichikawa K, Liu W, Zhao L, Wang Z, Liu D, Ohtsuka T, Zhang H, Mountz JD, Koopman WJ, Kimberly RP and Zhou T. (2001). Nat. Med., 7, 954-960.
53. Igney FH and Krammer PH. (2002). Nat. Rev. Cancer, 2, 277-288.
54. Inoue K, Slaton JW, Davis DW, Hicklin DJ, McConkey DJ, Karashima T, Radinsky R and Dinney CP. (2001). Clin. Cancer Res., 6, 2635-2643.
55. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer JL, Schroter M, Burns K, Mattmann C, Rimoldi D, French LE and Tschopp J. (1997). Nature, 388, 190-195.
56. Jain RK. (2002). Semin. Oncol., 29, 3-9.
57. Jones PT, Dear PH, Foote J, Neuberger MS and Winter G. (1986). Nature, 321, 522-525.
58. Kandasamy K and Srivastava RK. (2002). Cancer Res., 62, 4929-4937.
59. Kennedy SG, Wagner AJ, Conzen SD, Jordan J, Bellacosa A, Tsichlis PN and Hay N. (1997). Genes Dev., 11, 701-713.
60. Keppler-Hafkemeyer A, Kreitman RJ and Pastan I. (2000). Int. J. Cancer, 87, 86-94.
61. Kim ES, Khuri FR and Herbst RS. (2001). Curr. Opin. Oncol., 13, 506-513.
62. Kim J, Li B, Winer J, Armanini M, Gillett N, Phillip HS and Ferrara N. (1993). Nature, 362, 841-844.
63. Knappik A, Ge L, Honegger A, Pack P, Fischer M, Wellnhofer G, Hoess A, Wolle J, Pluckthun A and Virnekas B. (2000). J. Mol. Biol., 296, 57-86.
64. Kozin SV, Boucher Y, Hicklin DJ, Bohlen P, Jain RK and Suit HD. (2001). Cancer Res., 61, 39-44.
65. Kreitman RJ. (2001). Curr. Pharmacol. Biotechnol., 2, 313-325.
66. Kreitman RJ, Wilson WH, Robbins D, Margulies I, Stetler-Stevenson M, Waldmann TA and Pastan I. (1999). Blood, 94, 3340-3348.
67. Kreitman RJ, Wilson WH, White JD, Stetler-Stevenson M, Jaffe ES, Giardina S, Waldmann TA and Pastan I. (2000). J. Clin. Oncol., 18, 1622-1636.
68. Lee S, Yang W, Lan KH, Sellappan S, Klos K, Hortobagyi G, Hung MC and Yu D. (2002). Cancer Res., 62, 5703-5710.
69. Li B, Fuh G, Meng G, Xin X, Gerritsen ME, Cunningham B and De Vos AM. (2000). J. Biol. Chem., 275, 29823-29828.
70. Liu B and Fan Z. (2001). Oncogene, 20, 3726-3734.
71. Liu B, Fang M, Schmidt M, Lu Y, Mendelsohn J and Fan Z. (2000). Br. J. Cancer, 82, 1991-1999.
72. Mallat Z and Tedgui Z. (2000). Br. J. Pharmacol., 130, 947-962.
73. Maloney DG. (2001). Anticancer Drugs, 12S2, S1-S4.
74. Mandal M, Adam L, Mendelsohn J and Kumar R. (1998). Oncogene, 27, 999-1007.
75. Maung ZT, MacLean FR, Reid MM, Pearson AD, Proctor SJ, Hamilton PJ and Hall AG. (1994). Br. J. Haematol., 88, 105-109.
76. Mendelsohn J. (1990). Semin. Cancer Biol., 1, 339-344.
77. Mendelsohn J. (1997). Clin. Cancer Res., 3, 2703-2707.
78. Mendelsohn J. (2000). Clin. Cancer Res., 6, 747-753.
79. Mendez MJ, Green LL, Corvalan JR, Jia XC, Maynard-Currie CE, Yang XD, Gallo ML, Louie DM, Lee DV, Erickson KL, Luna J, Roy CM, Abderrahim H, Kirschenbaum F, Noguchi M, Smith DH, Fukushima A, Hales JF, Klapholz S, Finer MH, Davis CG, Zsebo KM and Jakobovits A. (1997). Nat. Genet., 15, 146-156.
80. Mesri M, Morales-Ruiz M, Ackermann EJ, Bennett CF, Pober JS, Sessa WC and Altieri DC. (2001). Am. J. Pathol., 158, 1757-1765.
81. Milas L, Mason K, Hunter N, Petersen S, Yamakawa M, Ang K, Mendelsohn J and Fan Z. (2000). Clin. Cancer Res., 6, 701-708.
82. Millauer B, Wizigmann-Voos S, Schnurch H, Martinez R, Moller NPH, Risau W and Ullrich A. (1993). Cell, 72, 835-846.
83. Miyashita T and Reed JC. (1993). Blood, 81, 151-157.
84. Monks NR, Blakey DC, Curtin NJ, East SJ, Heuze A and Newell DR. (2001). Br. J. Cancer, 85, 764-771.
85. Morrison SL, Johnson MJ, Herzenberg LA and Oi VT. (1984). Proc. Natl. Acad. Sci. USA, 81, 6851-6855.
86. Nagata S. (1997). Cell, 88, 355-365.
87. Nagata S and Golstein P. (1995). Science, 267, 1449-1456.
88. Napier MP, Sharma SK, Springer CJ, Bagshawe KD, Green AJ, Martin J, Stribbling SM, Cushen N, O'Malley D and Begent RH. (2000). Clin. Cancer Res., 6, 765-772.
89. Nicholson S, Sainsbury JR, Halcrow P, Chambers P, Farndon JR and Harris AL. (1989). Lancet, 1, 182-185.
90. Nor JE, Christensen J, Liu J, Peters M, Mooney DJ, Strieter RM and Polverini PJ. (2001). Cancer Res., 61, 2183-2188.
91. O'Connor DS, Schechner JS, Adida C, Mesri M, Rothermel AL, Li F, Nath AK, Pober JS and Altieri DC. (2000). Am. J. Pathol., 156, 393-398.
92. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, Itoh N, Suda T and Nagata S. (1993). Nature, 364, 806-809.
93. Ohtsuka T and Zhou T. (2002). J. Biol. Chem., 277, 29294-29303.
94. Ong SH, Hadari YR, Gotoh N, Guy GR, Schlessinger J and Lax I. (2001). Proc. Natl. Acad. Sci. USA, 98, 6074-6079.
95. Overholser JP, Prewett MC, Hooper AT, Waksal HW and Hicklin DJ. (2000). Cancer, 89, 74-82.
96. Pan G, Ni J, Wei YF, Yu G, Gentz R and Dixit VM. (1997). Science, 277, 815-818.
97. Pan G, Ni J, Yu G, Wei YF and Dixit VM. (1998). FEBS Lett., 424, 41-45.
98. Parrizas M, Saltiel AR and LeRoith D. (1997). J. Biol. Chem., 272, 154-161.
99. Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, Coombs D, Baly D, Kabbinavar F and Slamon D. (1999). Oncogene, 18, 2241-2251.
100. Peltenburg LT. (2000). Q. J. Nucl. Med., 44, 355-364.
101. Penuel E, Schaefer G, Akita RW and Sliwkowski MX. (2001). Semin. Oncol., 28, 36-42.
102. Pietras RJ, Poen JC, Gallardo D, Wongvipat PN, Lee HJ and Slamon DJ. (1999). Cancer Res., 59, 1347-1355.
103. Pollak M. (2000). Eur. J. Cancer, 36, 1224-1228.
104. Posey J, Yang B, Khazaeli M, Fox F, Engel J, Needle M and Wasksal H. (2002). Am. Soc. Clin. Oncol, (Proceedings of the 38th Annual meeting) 21, 17a (Abstract 63).
105. Press OW, Eary JF, Gooley T, Gopal AK, Liu S, Rajendran JG, Maloney DG, Petersdorf S, Bush SA, Durack LD, Martin PJ, Fisher DR, Wood B, Borrow JW, Porter B, Smith JP, Mathews DC, Appelbaum FR and Bernstein ID. (2000). Blood, 96, 2934-2942.
106. Presta LG. (2002). Curr. Pharmacol. Biotechnol., 3, 237-256.
107. Prewett M, Huber J, Li Y, Santiago A, O'Connor W, King K, Overholser J, Hooper A, Pytowski B, Witte L, Bohlen P and Hicklin DJ. (1999). Cancer Res., 59, 5209-5218.
108. Reed JC. (2002). Nat. Rev. Drug Discov., 1, 111-121.
109. Rosen LS. (2002). Cancer Control, 9, 36-44.
110. Rowan W, Tite J, Topley P and Brett SJ. (1998). Immunology, 95, 427-436.
111. Sasaki M, Kumazaki T, Tanimoto K and Nishiyama M. (2003). Int. J. Oncol., 22, 181-186.
112. Sato JD, Kawamoto T, Le AD, Mendelsohn J, Polikoff J and Sato GH. (1983). Mol. Biol. Med., 1, 511-529.
113. Scaffidi C, Schmitz I, Zha J, Korsmeyer SJ, Krammer PH and Peter ME. (1998). J. Biol. Chem., 274, 22532-22538.
114. Schier R, McCall A, Adams GP, Marshall KW, Merritt H, Yim M, Crawford RS, Weiner LM, Marks C and Marks JD. (1996). J. Mol. Biol., 263, 551-567.
115. Senter PD and Springer CJ. (2001). Adv. Drug Deliv. Rev., 53, 247-264.
116. Shaheen RM, Tseng WW, Vellagas R, Liu W, Ahmad SA, Jung YD, Reinmuth N, Drazan KE, Bucana CD, Hicklin DJ and Ellis LM. (2001). Int. J. Oncol., 18, 221-226.
117. Shan D, Ledbetter JA and Press OW. (2000). Cancer Immunol. Immunother., 48, 673-683.
118. Sheridan MT, O'Dwyer T, Seymour CB and Mothersill CE. (1997). Radiat. Oncol. Invest., 5, 180-186.
119. Shibuya M, Yamaguchi S, Yamane A, Ikeda T, Tojo A, Matsushime H and Sato M. (1990). Oncogene, 5, 519-524.
120. Sievers EL. (2000). Cancer Chemother. Pharmacol., 46, 18-22.
121. Sievers EL, Appelbaum FR, Spielberger RT, Forman SJ, Flowers D, Smith FO, Shannon-Dorcy K, Berger MS and Bernstein ID. (1999). Blood, 93, 3678-3684.
122. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL. (1987). Science, 235, 177-182.
123. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J and Norton L. (2001). N. Engl. J. Med., 344, 783-792.
124. Soffer SZ, Moore JT, Kim E, Huang J, Yokoi A, Manley C, O'Toole K, Stolar C, Middlesworth W, Yamashiro DJ and Kandel JJ. (2001). J. Pediatr. Surg., 36, 1177-1181.
125. Tedder TF and Engel P. (1994). Immunol. Today, 15, 450-454.
126. Terman BI, Dougher-Vermazen M, Carrion ME, Dimtrov D, Armellino DC, Gospodarowicz D and Bohlen P. (1992). Biochem. Biophys. Res. Commun., 187, 1579-1586.
127. Tortora G, Caputo R, Pomatico G, Pepe S, Bianco AR, Agrawal S, Mendelsohn J and Ciardiello F. (1999). Clin. Cancer Res., 5, 875-881.
128. Tran J, Rak J, Sheehan C, Saibil SD, LaCasse E, Korneluk RG and Kerbel RS. (1999). Biochem. Biophys. Res. Commun., 264, 781-788.
129. Trauth BC, Klas C, Peters AM, Matzku S, Moller P, Falk W, Debatin KM and Krammer PH. (1989). Science, 245, 301-305.
130. van der Kolk LE, Evers LM, Omene C, Lens SM, Lederman S, van Lier RA, van Oers MH and Eldering E. (2002). Leukemia, 16, 1735-1744.
131. Vaughan TJ, Osbourn JK and Tempest PR. (1998). Nat. Biotechnol., 16, 535-539.
132. Volm M, Efferth T and Mattern J. (1992). Anticancer Res., 12, 11-20.
133. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M and Heldin CH. (1994). J. Biol. Chem., 269, 26988-26995.
134. Ward ES and Ghetie V. (1995). Ther. Immunol., 2, 77-94.
135. Winter G and Milstein C. (1991). Nature, 349, 293-299.
136. Witte L, Hicklin DJ, Zhu Z, Pytowski B, Kotanides H, Rockwell P and Bohlen P. (1998). Cancer Metast. Rev., 17, 155-161.
137. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, Grillo-Lopez AJ, Multani P and White CA. (2002). J. Clin. Oncol., 20, 2453-2463.
138. Witzig TE, White CA, Wiseman GA, Gordon LI, Emmanouilides C, Raubitschek A, Janakiraman N, Gutheil J, Schilder RJ, Spies S, Silverman DH, Parker E and Grillo-Lopez AJ. (1999). J. Clin. Oncol., 17, 3793-3803.
139. Wu X, Fan Z, Masui H, Rosen N and Mendelsohn J. (1995). J. Clin. Invest., 95, 1897-1905.
140. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S and Arteaga CL. (2002). Cancer Res., 62, 4132-4141.
141. Yarnold S and Fell HP. (1994). Cancer Res., 54, 506-512.
142. Zhang L, Yu D, Hicklin DJ, Hannay JAF, Ellis LM and Pollock RE. (2002). Cancer Res., 62, 2034-2042.
143. Zhu Z, Bohlen P and Witte L. (2002). Curr. Cancer Drug Targets, 2, 135-156.